Table 1. Baseline Characteristics of the Study Population.
| Characteristic | Statin (n=72) | Placebo (n=75) |
|---|---|---|
| Age (years) | 45.6 (41.1-51.4) | 46.9 (39.2-53.6) |
| Male | 58 (81) | 57 (76) |
| African American | 51 (71) | 52 (69) |
| Current smoker | 43 (60) | 54 (72) |
| Body mass index (kg/m2) | 26.6 (23.4-30.0) | 27.2 (23.5-30.5) |
| Family history hip fracture | 6 (8) | 12 (16) |
| Hepatitis C | 5 (7) | 7 (9) |
| CD4+ lymphocyte count (cells/μL) | 608 (440-848) | 627 (398-853) |
| Nadir CD4+ T-cell count (cells/μL) | 173 (84-312) | 190 (89-281) |
| HIV-1 RNA <50 copies/mL | 56 (78) | 58 (77) |
| Antiretroviral therapy duration (months) | 63 (37-119) | 71 (39-116) |
| Current protease inhibitor-containing regimen | 36 (50) | 36 (48) |
| Current tenofovir-containing regimen | 64 (89) | 66 (88) |
| Total hip osteopenia or osteoporosis | 18 (25) | 17 (22) |
| Lumbar spine osteopenia or osteoporosis | 19 (26) | 13 (17) |
Values presented as median (25th, 75th percentile) or number (%).